Correlation Engine 2.0
Clear Search sequence regions

  • adult (3)
  • BAX (9)
  • child (1)
  • children (2)
  • half- life (5)
  • hemophilia (3)
  • hemostatics (2)
  • humans (1)
  • patients (2)
  • Sizes of these terms reflect their relevance to your search.

    Limited sampling strategies (LSS) lower the burden of pharmacokinetic (PK)-guided dosing, but an extensive evaluation of LSS for BAX 855 (Adynovi) is currently lacking. This study aimed to develop a LSS for BAX 855 and combine this with a LSS of a standard half-life (SHL) factor VIII (FVIII) concentrate in a clinical setting. Individual PK parameters of BAX 855 were estimated for 10 000 virtual patients with severe hemophilia A using Monte Carlo simulations. Several LSS consisting of 2-6 samples were examined based on patient burden, bias and accuracy of clearance, elimination half-life, volume of distribution and trough levels at 72 h (C72). Analyses were performed separately for adults and children <12 years. The preferred LSS for BAX 855 consisted of three sampling points at 15-30 min, 48 h and 72 h for both adults (mean accuracy C72: 14.0% vs. 10.8% using six samples) and children (mean accuracy C72: 14.9% vs. 11.4% using six samples). The best strategy with two samples (peak, 48 h) resulted in an adequate, but lower accuracy than strategies with ≥3 samples (mean accuracy C72: 22.3%). The optimal combination of the LSS of SHL FVIII and BAX 855 led to six samples during four clinical visits. This in silico study has identified that two to three samples are necessary to estimate the individual PK of BAX-855 adequately. These samples can be collected in one or two clinical visits. When combining PK profiling of SHL FVIII and BAX 855, six samples during four clinical visits are needed. Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.


    Laura H Bukkems, Tine M H J Goedhart, C Michel Zwaan, Marjon H Cnossen, Ron A A Mathôt, OPTI-CLOT study group, SYMPHONY consortium. Limited sampling strategies for individualized BAX 855 prophylaxis in severe hemophilia A: in silico evaluation. Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis. 2023 Apr 01;34(3):171-178

    Expand section icon Mesh Tags

    Expand section icon Substances

    PMID: 37038844

    View Full Text